06:40 EST Insulet (PODD) sees Q4 revenue growth 25%-28% from $597.5M last year, consensus $729.9M
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet reports Q3 adjusted EPS $1.24, consensus $1.15
- Insulet price target raised to $301 from $300 at Barclays
- PODD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insulet’s New Study on Simplified Onboarding for Type 2 Diabetes Management: A Potential Game Changer
- Insulet’s Omnipod 5 Study: A Real-World Evaluation of Diabetes Management